RxDoctor Payments DataLook up a doctor →

Archana Sharma, MD

Rheumatology · Bristol, CTNPI 1851524557

Payments from drug & device makers

$97,611in general payments, 2019–2025

Across 601 payments — averaging $162.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$90K
  • Amgen$2K
  • Lilly USA, LLC$596
  • Mallinckrodt Hospital Products Inc.$498
  • Johnson & Johnson$471
  • GSK$437
  • plus $4K from 36 others

What the payments were for

  • Consulting fees$1000%
  • Speaking & faculty fees$66,45068%
  • Travel & lodging$18,88219%
  • Food & beverage$11,88912%
  • Education$2900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,611 in reported general payments places this provider in the 85th percentile of 118 rheumatology providers in Connecticut.

See all rheumatology providers in Connecticut

Medicare billing

Part B allowed, 2024
$26,181
Medicare patients
155
Services billed
258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib107$710,997
Humira(Cf) PenAdalimumab86$675,853
Orencia ClickjectAbatacept70$411,424
Enbrel SureclickEtanercept45$326,175
Xeljanz XrTofacitinib Citrate23$187,485
Enbrel MiniEtanercept15$110,705
OtezlaApremilast14$72,126
Actemra ActpenTocilizumab19$66,895
OrenciaAbatacept12$60,857
Hydroxychloroquine Sulfate519$15,322
RasuvoMethotrexate/Pf13$8,661
MethotrexateMethotrexate Sodium401$6,164
Leflunomide106$5,467
Lidocaine22$4,937
Gabapentin180$4,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$90,423$710,997107 claims
AmgenOtezla$1,564$72,12614 claims
E.r. Squibb & Sons, L.L.C.Orencia$172$60,85712 claims
Medexus Pharma, Inc.Rasuvo$13$8,66113 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$18$1,86531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 118 rheumatology providers in Connecticut.

Other rheumatology in Bristol

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →